The multiple myeloma treatment landscape has undergone a revolution in recent years that has resulted in potent individualized approaches that can be utilized in varied patient populations and clinical settings. Immunomodulatory imide drugs (IMiDs) and proteasome inhibitors (PIs), CD38 or SLAMF7 antibodies, and targeted agents can now be employed in potent doublet, triplet, or quadruplet regimens. New treatment options, pending evidence, include novel antibodies and cellular therapies directed against the B-cell maturation antigen. Crafting treatment regimens for patients with multiple myeloma that integrate emerging therapies requires an understanding of the data and guidelines for these therapeutics and strategies for managing related adverse events.
These PeerView activities offer an expert overview of recent data and discussion on navigating the new era of multiple myeloma treatment across diverse clinical presentations—watch the experts to hear the latest recommendations!
This series of activities has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, and other clinicians involved in the management of multiple myeloma.
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Request to have one of our experts lead a meeting at your institution! In a small group setting, hear a multiple myeloma expert discuss innovations in the treatment landscape and best practices for applying evidence-based guidelines into your practice.
Download and complete the Meeting Request Form (or complete our online form) to request a live in-person meeting or turn-key virtual meeting with our expert faculty.
By requesting a meeting, you are attesting that you have read the CME/MOC Information for this activity.
Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, will be joined by Shaji Kumar, MD, Robert Z. Orlowski, MD, PhD, and Nina Shah, MD, as expert presenters for this educational activity.
Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, Shaji Kumar, MD, Robert Z. Orlowski, MD, PhD, and Nina Shah, MD
This educational curriculum is supported by educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi US.
Your meeting request has been submitted.
We invite you to learn more about PeerView's Regional Meetings here.
